May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Can the mfERG Be Used to Follow-up AMD Patients after PDT and Predict the Need for Retreatment?
Author Affiliations & Notes
  • M. Fredette
    Ophthalmology, Université Laval, Quebec City, PQ, Canada
  • H. Shekavat
    Ophthalmology, Université Laval, Quebec City, PQ, Canada
  • G. Lalonde
    Ophthalmology, Centre Hospitalier Universitaire Quebec, Quebec City, PQ, Canada
  • B. Cinq-Mars
    Ophthalmology, Centre Hospitalier Universitaire Quebec, Quebec City, PQ, Canada
  • Y. Tardif
    Ophthalmology, Centre Hospitalier Universitaire Quebec, Quebec City, PQ, Canada
  • M. Malenfant
    Ophthalmology, Centre Hospitalier Universitaire Quebec, Quebec City, PQ, Canada
  • M. Hebert
    Ophthalmology, Laval University Hospital (CHUL) Research Centre, Quebec city, PQ, Canada
  • Footnotes
    Commercial Relationships  M. Fredette, None; H. Shekavat, None; G. Lalonde, None; B. Cinq-Mars, None; Y. Tardif, None; M. Malenfant, None; M. Hebert, None.
  • Footnotes
    Support  FRSQ, Vision Network
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1831. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      M. Fredette, H. Shekavat, G. Lalonde, B. Cinq-Mars, Y. Tardif, M. Malenfant, M. Hebert; Can the mfERG Be Used to Follow-up AMD Patients after PDT and Predict the Need for Retreatment? . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1831.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose : A decrease in the central mfERG peak time latencies seems to occur following PDT. Our goal was to further document this finding in non-dilated eyes, before and after PDT and see if we could identify a latency criterion that could be used to predict the need for retreatment. Methods :18 AMD patients (mean age: 72±11 y.o.) with CNV had a mfERG followed by PDT. Stimulus consisted in a 61-hexagon matrix with the mean luminance set at 400 cd/m-2. Recordings (DTL), were obtained using 16 segments of 15 sec each. Signal was filtered (10-100 Hz) and amplified (100,000x). P1 latency was measured for each Ring (5). Results : P1 latency of 35 msec or higher was present in 100%, 72%, 56%, 50% and 50% in Rings 1,2,3,4 and 5 respectively. The mean latency ±SD of Ring 1 and 2 were 38.9±3.5 msec and 37.1±3.5 msec respectively. One month after PDT in 10 patients retested so far, P1 latency in Ring 1, was significantly decreased by 3.0 msec on average (p=0.01). After 2-5 months, a return to pre-PDT value was observed in all 10 patients. Fluorescein angiogram obtained at 3-5 months after PDT in 6 patients so far, confirmed the presence of leakage along with a P1 latency of 35 msec or higher in Ring 1 (N=5) and Ring 2 (N=1; parafoveal leakage). Conclusions: Our data suggest that a latency of at least 35 msec is present in Ring 1 when CNV is present or when leakage (post-PDT) occurs. P1 latency in Ring1 appears to be useful to follow-up patients with CNV and predict the need for retreatment. The mfERG as obtained in non-dilated eye, could become a useful tool to follow-up patients more regularly especially if earlier retreatment is recommended in the near future.<br

Keywords: electroretinography: clinical • age-related macular degeneration • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×